A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Adenoviridae
/ genetics
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
B-Lymphocytes
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Immunity, Cellular
/ immunology
Immunity, Humoral
/ immunology
Immunoglobulin G
/ immunology
Mice
Mice, Inbred BALB C
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
T-Lymphocytes
/ immunology
Vaccination
Adenovirus
COVID-19
Infectious diseases
Recombinant DNA vaccines
SARS-CoV-2
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
27
02
2021
received:
05
01
2021
accepted:
16
03
2021
pubmed:
28
3
2021
medline:
15
7
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
Optimal vaccines are needed for sustained suppression of SARS-CoV-2 and other novel coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the gene for the SARS-CoV-2 S1 subunit antigen (Ad5.SARS-CoV-2-S1) for COVID-19 immunization and evaluated its immunogenicity in mice. A single immunization with Ad5.SARS-CoV-2-S1 via S.C. injection or I.N delivery induced robust antibody and cellular immune responses. Vaccination elicited significant S1-specific IgG, IgG1, and IgG2a endpoint titers as early as 2 weeks, and the induced antibodies were long lasting. I.N. and S.C. administration of Ad5.SARS-CoV-2-S1 produced S1-specific GC B cells in cervical and axillary LNs, respectively. Moreover, I.N. and S.C. immunization evoked significantly greater antigen-specific T-cell responses compared to unimmunized control groups with indications that S.C. injection was more effective than I.N. delivery in eliciting cellular immune responses. Mice vaccinated by either route demonstrated significantly increased virus-specific neutralization antibodies on weeks 8 and 12 compared to control groups, as well as BM antibody forming cells (AFC), indicative of long-term immunity. Thus, this Ad5-vectored SARS-CoV-2 vaccine candidate showed promising immunogenicity following delivery to mice by S.C. and I.N. routes of administration, supporting the further development of Ad-based vaccines against COVID-19 and other infectious diseases for sustainable global immunization programs.
Identifiants
pubmed: 33772778
doi: 10.1002/eji.202149167
pmc: PMC8250272
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1774-1784Subventions
Organisme : NCI NIH HHS
ID : P50 CA159981
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137132
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR071277
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR074285
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233085
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI130180
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI043603
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI043603
Pays : United States
Informations de copyright
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Vaccine. 2005 Jan 11;23(8):1029-36
pubmed: 15620476
Sci Total Environ. 2020 Aug 15;730:138996
pubmed: 32371230
J Immunol. 1997 Feb 1;158(3):1268-74
pubmed: 9013969
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Curr Opin Immunol. 2016 Aug;41:47-54
pubmed: 27286566
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Vaccine. 2014 Oct 14;32(45):5975-82
pubmed: 25192975
Adv Drug Deliv Rev. 2021 Apr;171:164-186
pubmed: 33539853
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Sci Total Environ. 2020 Aug 1;728:138882
pubmed: 32335410
Nat Rev Microbiol. 2010 Jan;8(1):62-73
pubmed: 19966816
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32161092
Curr Trop Med Rep. 2020;7(2):61-64
pubmed: 32219057
EBioMedicine. 2020 May;55:102743
pubmed: 32249203
Antiviral Res. 2020 Jun;178:104792
pubmed: 32272173
Expert Rev Vaccines. 2009 Jun;8(6):761-77
pubmed: 19485756
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3041-6
pubmed: 23386724
Clean Technol Environ Policy. 2020;22(3):545-546
pubmed: 32292319
Drugs Today (Barc). 2018 May;54(5):315-333
pubmed: 29911696
J Virol. 2013 Nov;87(21):11950-4
pubmed: 23986586
J Control Release. 2020 Jan 10;317:336-346
pubmed: 31756393
Vaccine. 2016 Jan 20;34(4):413-423
pubmed: 26691569
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Invest Dermatol. 2020 Dec;140(12):2528-2531.e2
pubmed: 32330464
Vaccine. 2018 Jun 7;36(24):3468-3476
pubmed: 29739720
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Emerg Microbes Infect. 2020 Dec;9(1):542-544
pubmed: 32148172
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
J Virol. 1997 Mar;71(3):1842-9
pubmed: 9032314
Curr Opin Immunol. 2009 Jun;21(3):346-51
pubmed: 19500964
Immunol Rev. 2012 May;247(1):52-63
pubmed: 22500831
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
Acta Biomater. 2018 Oct 15;80:31-47
pubmed: 30172933
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Genet Vaccines Ther. 2004 Dec 03;2(1):17
pubmed: 15579202
Vaccine. 2014 May 30;32(26):3169-3174
pubmed: 24736006
Front Microbiol. 2019 Aug 02;10:1781
pubmed: 31428074
Cell Stress. 2020 Mar 02;4(4):66-75
pubmed: 32292881
N Engl J Med. 2017 Mar 9;376(10):928-938
pubmed: 25426834
Nat Med. 1996 Oct;2(10):1122-8
pubmed: 8837611
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Immunity. 2006 May;24(5):643-56
pubmed: 16713981
Vaccine. 2009 Nov 12;27(48):6723-30
pubmed: 19748577
Lancet. 2020 Apr 18;395(10232):1247
pubmed: 32305089
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
Curr Opin Immunol. 1998 Jun;10(3):252-8
pubmed: 9638360
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Nat Biotechnol. 2013 Dec;31(12):1082-5
pubmed: 24316643
Antiviral Res. 2013 Oct;100(1):286-95
pubmed: 24012996
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
EBioMedicine. 2016 Nov;13:315-320
pubmed: 27717627
Lancet Infect Dis. 2016 Mar;16(3):311-20
pubmed: 26725450
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Nat Rev Immunol. 2020 Feb;20(2):87-88
pubmed: 31712767
Vaccine. 2017 Oct 4;35(41):5437-5443
pubmed: 28216184
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Viruses. 2020 Jan 29;12(2):
pubmed: 32013152
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Lancet. 2003 Dec 6;362(9399):1895-6
pubmed: 14667748
Vaccine. 2017 Aug 16;35(35 Pt A):4461-4464
pubmed: 28576573
Curr Opin Immunol. 2020 Aug;65:21-27
pubmed: 32259744
Mol Ther. 2004 Oct;10(4):616-29
pubmed: 15451446
Emerg Microbes Infect. 2016 Apr 06;5:e33
pubmed: 27048742
Mayo Clin Proc. 2020 Oct;95(10):2172-2188
pubmed: 33012348
Front Immunol. 2019 Mar 27;10:594
pubmed: 30972078
Biotechnol Prog. 2004 Mar-Apr;20(2):443-8
pubmed: 15058988
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Vaccine. 2008 Nov 25;26(50):6338-43
pubmed: 18824060
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Mol Ther. 2008 Sep;16(9):1609-16
pubmed: 18612271
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480